Halozyme Therapeutics (HALO) Research & Development (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Research & Development data on file, last reported at $25.6 million in Q1 2026.

• On a quarterly basis, Research & Development rose 72.71% year-over-year to $25.6 million in Q1 2026; TTM through Mar 2026 was $92.3 million, a 23.44% increase from a year earlier, with the FY2025 full-year figure at $81.5 million, up 3.09% from the prior year.
• Research & Development for Q1 2026 stood at $25.6 million, down from $31.9 million in the prior quarter.
• Over the last five years, Research & Development for HALO reached as high as $31.9 million in Q4 2025 and fell as low as $11.9 million in Q1 2022.
• Historically, Research & Development has averaged $19.4 million across 5 years, with a median of $18.5 million in 2024.
• Across the five-year window, Research & Development jumped 123.25% in 2022 and dropped 22.56% in 2025, its largest moves.
• Year by year, Research & Development stood at $22.6 million in 2022, then fell by 5.45% to $21.3 million in 2023, then fell by 4.19% to $20.4 million in 2024, then surged by 56.04% to $31.9 million in 2025, then fell by 19.87% to $25.6 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $25.6 million in Q1 2026, $31.9 million in Q4 2025, and $17.3 million in Q3 2025.